<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487445</url>
  </required_header>
  <id_info>
    <org_study_id>ID-076A202</org_study_id>
    <secondary_id>2018-000765-36</secondary_id>
    <nct_id>NCT03487445</nct_id>
  </id_info>
  <brief_title>A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack</brief_title>
  <official_title>A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find out how fast a drug called ACT-246475 can prevent platelets
      from binding together. This study will also help to find out more about the safety of this
      new drug. The drug ACT-246475 will be used in 2 different doses (8 mg or 16 mg) and will be
      administered in the thigh.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 16, 2018</start_date>
  <completion_date type="Anticipated">October 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to the treatment defined for each subject as a P2Y12 reaction units value &lt; 100 at the 30 min post-dose time point, as measured via VerifyNowÂ®. This corresponds to an inhibition of ADP-induced platelet aggregation &gt; 80%.</measure>
    <time_frame>30 min post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>ACT-246475 - 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single s.c. administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-246475 - 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single s.c. administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-246475</intervention_name>
    <description>ACT-246475 for s.c. administration will be available as sealed glass vials in 20 mg strength</description>
    <arm_group_label>ACT-246475 - 8 mg</arm_group_label>
    <arm_group_label>ACT-246475 - 16 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Informed consent obtained prior to any study-mandated procedure,

          -  Males aged from 18 to 85 and postmenopausal females aged up to 85 years,

          -  Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to
             randomization,

          -  Subjects presenting a type I AMI including STEMI or NSTEMI.

        Main Exclusion Criteria:

          -  Cardiogenic shock or severe hemodynamic instability,

          -  Cardiopulmonary resuscitation,

          -  Loading dose of any oral P2Y12 receptor antagonist prior to randomization,

          -  Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h
             prior to randomization,

          -  Known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand
             disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marie Frenoux</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Disclosure desk</last_name>
    <phone>+41 58 844 00 00</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

